Accéder au contenu
Merck

Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability.

International journal of pharmaceutics (2012-03-15)
Sonali V Kapse, Rajiv V Gaikwad, Abdul Samad, Padma V Devarajan
RÉSUMÉ

We disclose a self nanoprecipitating preconcentrate (SNP) of tamoxifen citrate (TMX), which forms TMX loaded polymeric nanoparticles, on dilution with aqueous media. SNP comprised TMX, polymer (Kollidon SR) and surfactant/s dissolved in a pharmaceutically acceptable vehicle. Binary surfactant mixtures of Aerosol OT (AOT) with Tween 80 revealed synergistic reduction in surface tension to enable both high entrapment efficiency (EE) and low particle size (PS). Synergism of the surfactants was confirmed by molecular interaction parameter(β(σ)). Combination of AOT and Tween 80 resulted in EE (∼85%) and PS (<250nm). Formation of TMX-KSR nanoparticles in situ was reproducible under most experimental conditions and exhibited pH independent behavior. Dilution volume (>80mL) influenced both PS and EE while dilution temperature influenced only PS. Marginal increase in size was evident at the end of 1h nevertheless was not of concern as TMX SNP exhibited near complete release in 1h. DSC and XRD studies revealed amorphous nature of TMX in nanoparticles. FTIR imaging confirmed uniform distribution of TMX in nanoparticles. ESEM and TEM revealed spherical nanoparticles. Biodistribution studies of (99m)Tc labeled TMX SNP in rats revealed no significant absorption however oral pharmacokinetics revealed enhanced oral bioavailability of TMX (165%) compared to TMX suspension. SNP presents a new in situ approach, for design of drug loaded polymeric nanoparticles.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dioctyl sulfosuccinate sodium salt, ≥97%
Sigma-Aldrich
Docusate sodium salt, BioXtra, ≥99%
Sigma-Aldrich
Docusate sodium salt, BioUltra, ≥99.0% (TLC)
Sigma-Aldrich
Docusate sodium, meets USP testing specifications
Sigma-Aldrich
Docusate sodium salt, purum, ≥96.0% (TLC)